投融资数据库
免费查数据
注册送3天会员
首页>投融资
Lycia Therapeutics
C轮
Lycia Therapeutics Inc, established in 2019, is a biotechnology company using its lysosomal targeting chimeras (LYTACs) platform to discover and develop first-in-class therapeutics that degrade extracellular and membrane-bound proteins that drive a range of difficult-to-treat diseases, including cancers and autoimmune conditions.In September 2021, Lycia Therapeutics Inc completed oversubscribed $70 million Series B financing round
基本信息
-
公司全称Lycia Therapeutics Inc
-
类型蛋白质降解药物研发商
-
产业领域医药研发/制造、化学&生物药
-
公司人数15人以下
-
地址681 Gateway Blvd. 3Rd Floor SOUTH SAN FRANCISCO CALIFORNIA 92121; US; Telephone: +16506868821;
-
联系电话
-
邮箱info@lyciatx.com
-
成立时间2019-01-01
投融资
-
2024-05-13
-
2021-09-09
-
2020-06-10
相关投融资企业
E~PreIPO
Arthrosi Therapeutics LLC focuses on the treatment of uric acid levels and reduce joint damage for people living with gout.In July 2023, Arthrosi Therapeutics secured of $75 million in Series D financing
E~PreIPO
Arthrosi Therapeutics LLC focuses on the treatment of uric acid levels and reduce joint damage for people living with gout.In July 2023, Arthrosi Therapeutics secured of $75 million in Series D financing
收并购
Kronos Bio, Inc.于2017年6月2日根据特拉华州法律成立。该公司是一家临床阶段的生物制药公司，致力于发现和开发新的癌症疗法，旨在通过针对失调转录的精确药物策略来改变患者的预后。
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息